Literature DB >> 15668636

The systemic inflammatory response predicts overall and cancer specific survival in patients with malignant lymphoma.

Maqsood M Elahi1, Donald C McMillan, Colin S McArdle, Wilson J Angerson, Michael Soukop, Jennie Johnstone, Naveed Sattar.   

Abstract

BACKGROUND: The value of C-reactive protein concentrations in the assessment of prognosis in patients with advanced lymphoma has not been clearly defined. MATERIAL/
METHODS: Patients with a diagnosis of non-Hodgkin's lymphoma (n = 108) and Hodgkin's lymphoma, (n = 39) and who had measurements of C-reactive protein were studied retrospectively and the data was reviewed over 8 years.
RESULTS: Median survival, from the time of sampling, was 7.4 months. On univariate analysis there was a significant relationship between the duration of cancer specific survival and tumour type (p < 0.05), circulating concentrations of albumin (p < 0.001) and C-reactive protein (p < 0.001). In contrast, only C-reactive protein concentration was a predictor of death from intercurrent disease (p < 0.05). On multivariate analysis, C-reactive protein concentration remained a strong independent predictor of both death from cancer and intercurrent disease (p < 0.001). The hazard ratio associated with a unit increase in stratified C-reactive protein concentration was 8.18 (95% CI 4.80 - 13.95) for cancer specific death and 2.11 (95% CI 1.22 - 3.64) for intercurrent death.
CONCLUSIONS: The results of the present study demonstrate that patients with advanced lymphoma have evidence of a systemic inflammatory response and the magnitude of the C-reactive protein response predicts the duration of overall and cancer specific survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15668636

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  3 in total

1.  A pooled analysis of three studies evaluating genetic variation in innate immunity genes and non-Hodgkin lymphoma risk.

Authors:  H Dean Hosgood; Mark P Purdue; Sophia S Wang; Tongzhang Zheng; Lindsay M Morton; Qing Lan; Idan Menashe; Yawei Zhang; James R Cerhan; Andrew Grulich; Wendy Cozen; Meredith Yeager; Theodore R Holford; Claire M Vajdic; Scott Davis; Brian Leaderer; Anne Kricker; Maryjean Schenk; Shelia H Zahm; Nilanjan Chatterjee; Stephen J Chanock; Nathaniel Rothman; Patricia Hartge; Bruce Armstrong
Journal:  Br J Haematol       Date:  2011-01-20       Impact factor: 6.998

2.  The Levels of Serum C-Reactive Protein, Beta 2 Microglobulin, Ferritin, Lactate Dehydrogenase and Some Specific Proteins in Patients with Non-Hodgkin's Lymphoma Before and After Treatment.

Authors:  Rahsan Yildirim; Mehmet Gundogdu; Fuat Erdem; Lhami Kiki; Mehmet Bilici
Journal:  Eurasian J Med       Date:  2009-12

3.  C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.

Authors:  K T Troppan; K Schlick; A Deutsch; T Melchardt; A Egle; T Stojakovic; C Beham-Schmid; L Weiss; D Neureiter; K Wenzl; R Greil; P Neumeister; M Pichler
Journal:  Br J Cancer       Date:  2014-05-29       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.